Xanax®
Alprazolam
Version 2025-04 · Last reviewed April 1, 2025 · Methodology
List Price
$300+
With Insurance
$10–25
The Short Version
Plain-language summary
Xanax (Alprazolam) calms your nervous system fast by boosting a brain chemical called GABA. It works quickly for panic and anxiety, but the brain adapts to it within weeks, making it difficult to stop and meant only for short-term use.
How it works: Alprazolam amplifies the brain's primary inhibitory system. It attaches to GABA-A receptors and acts like a turbocharger, GABA normally calms neural activity, and alprazolam makes every GABA signal dramatically more powerful.
What people most commonly report
Never stop abruptly, requires a supervised taper; this is expected
Most studies were paid for by the company that makes this drug.
What Else the Evidence Supports
Non-drug options with clinical backing
CBT produces equal or better outcomes to benzodiazepines at 12 months, without addiction or withdrawal
Equal efficacy to benzos at 12 months; lower relapse; no dependence.
Reduces anxiety symptoms 48%; comparable to low-dose benzodiazepine.
RCT: significant reduction in mild-to-moderate anxiety.
Activates parasympathetic nervous system; reduces cortisol measurably.
What This Really Costs
Long-term cost projection based on current pricing
Monthly
$55
$18 w/ insurance
without insurance
Annual
$660
$216 w/ insurance
without insurance
10 Years
$6.6K
$2.2K w/ insurance
without insurance
30 Years
$19.8K
$6.5K w/ insurance
without insurance
Lifestyle alternative: $0/month in prescriptions. Cognitive Behavioral Therapy (CBT) - Equal efficacy to benzos at 12 months; lower relapse; no dependence.
The average American retiree spends $165,000 on healthcare after retirement (Fidelity, 2024). Informed choices today compound over decades.
Related Evidence
Explore related medications reviewed on EvidentMeds
Metabolic & Lifestyle Alternatives
Anxiety Without Dependency: Evidence-Based Alternatives
CBT produces equal or better outcomes to benzodiazepines at 12 months, without addiction or withdrawal
Important context: Evidence quality varies across these approaches. Some are well-studied with randomized controlled trial data; others are based on observational or smaller studies. These interventions are not guaranteed to replace medication for all patients. Discuss with your doctor whether any of these are appropriate for your clinical situation.
Cognitive Behavioral Therapy (CBT)
12–16 sessions
Equal efficacy to benzos at 12 months; lower relapse; no dependence
Aerobic exercise
30 min, 3–5x/week
Reduces anxiety symptoms 48%; comparable to low-dose benzodiazepine
Magnesium glycinate
300–400mg at night
RCT: significant reduction in mild-to-moderate anxiety
Diaphragmatic breathing / 4-7-8 technique
10 min twice daily
Activates parasympathetic nervous system; reduces cortisol measurably
Ashwagandha (KSM-66)
300–600mg/day
RCT: 56% reduction in anxiety scores vs 30% placebo
Global Prescribing & Pricing
US prescribes benzodiazepines at 5× the rate of most European countries
United States
$30–80 (generic)/mo
1 in 8 adults prescribed a benzodiazepine annually, highest globally
No mandatory therapy prerequisite; any physician can prescribe; refills readily available
Usually covered
United Kingdom
~$5–15/mo
Lower prescribing, strict NICE 2–4 week limit
NICE guidelines mandate maximum 2–4 weeks prescribing; therapy first for anxiety disorders
Covered by NHS with restrictions
France
~$5–12/mo
Still higher than northern Europe but 2.5× lower than US
Psychotherapy must be offered alongside; maximum 12-week prescription; tight renewal controls
Covered by Sécurité Sociale with restrictions
Germany
~$8–18/mo
Significantly lower, psychotherapy pathway well-funded
GKV subsidizes CBT wait times; strict 2–4 week acute use guidelines; no long-term prescribing
Covered by GKV with restrictions
Australia
~$15–30/mo
Lower prescribing; PBS limits quantities
PBS restricts repeats; quantity limits; prescriber must document acute indication
PBS limited quantities
The UK's 2–4 week maximum prescribing rule for benzodiazepines, combined with NHS-funded CBT, means the vast majority of anxiety patients receive effective therapy rather than a dependency-forming pill. The US has no equivalent national guideline, producing the world's highest benzo prescribing rate.
Clinical Trials & Funding
Understanding who funds research helps contextualize results. Industry-funded trials are not automatically invalid - they undergo the same FDA review - but declared conflicts and sponsor effects are worth knowing. All linked trials can be verified on ClinicalTrials.gov.
Key Efficacy Results
70–80% short-term symptom reduction; 40–60% develop physical dependence after 6 weeks; efficacy wanes with tolerance
Referenced Studies
Each study shows its evidence level and Cochrane RoB-2 risk-of-bias rating - tap the bias badge for details.
Evidence & Transparency
Cochrane RoB-2 (Risk of Bias)
Badges reflect an editorial assessment using Cochrane's RoB-2 tool domains: randomization, intervention deviation, missing data, outcome measurement, and selective reporting. These are not certified Cochrane reviews. Learn more ↗
CMS Open Payments
Manufacturer payment disclosures are reported via the CMS Sunshine Act. Disclosure is legally required and does not imply bias or misconduct. Language uses "may," "suggests," or "appears", never definitive clinical claims. CMS Open Payments ↗
Live Clinical Trials
Live from ClinicalTrials.gov · refreshed every 4 hours
Currently enrolling, active, and recently completed studies involving Alprazolam. Data is pulled directly from the U.S. National Library of Medicine.
Recent Research
Live from PubMed · peer-reviewed literature · refreshed every 4 hours
Most recently indexed clinical trials and systematic reviews mentioning Alprazolam in PubMed.
Source Documentation
Structured citations for referenced clinical trials
Each referenced trial is listed with its registry ID, funding source, and bias assessment. Use the copy button to generate a formatted citation.
| Trial | Registry ID | Cite |
|---|---|---|
| NIMH Anxiety Disorders Study | NCT00000393 | |
| Cross-National Panic Study | PMID:3524107 |
Bias ratings use Cochrane RoB-2 methodology. Editorial assessment - not a certified Cochrane review.
Our MethodologyCommon Side Effects
While taking this medication, you may experience the following common side effects. We've included tips on how to manage them.
Sedation / drowsiness
41%Take at bedtime if possible; avoid driving or operating machinery
Memory impairment
30%Do not take before important events or tasks requiring recall
Coordination problems / ataxia
20%Especially dangerous in elderly, eliminate fall hazards at home
Rebound anxiety when stopping
>50%Never stop abruptly, requires a supervised taper; this is expected
Tolerance (reduced efficacy over time)
40%+Limit use to <4 weeks; dependence risk increases sharply beyond this
Sexual dysfunction
10%Discuss with prescriber; often improves with dose reduction
Serious Adverse Effects
- • Physical dependence and addiction (40–60% of patients using >6 weeks)
- • Withdrawal seizures if stopped abruptly, can be life-threatening
- • Respiratory depression when combined with opioids or alcohol
- • Long-term cognitive impairment with chronic use
Drug Interactions
Major Interactions (Avoid)
Moderate Interactions (Caution)
Food Interactions
When to Contact Your Doctor
This medication requires ongoing medical supervision. The following situations warrant a prompt conversation with your prescribing physician - do not wait for your next scheduled appointment.
Contact soon if you notice
- Physical dependence and addiction (40–60% of patients using >6 weeks)
- Withdrawal seizures if stopped abruptly, can be life-threatening
- Respiratory depression when combined with opioids or alcohol
- Long-term cognitive impairment with chronic use
- Seizures, call 911 immediately
Also discuss if you want to
- Review whether this medication is still appropriate for you
- Consider dosage adjustments based on response
- Explore lifestyle or non-drug alternatives
- Understand stopping or tapering options
- Plan monitoring labs and follow-up
In the US, call 911 or go to the nearest emergency room for severe symptoms. Poison Control: 1-800-222-1222.
Special Populations
Safety classifications for specific groups - discuss with your provider before use.
Category D. Neonatal benzodiazepine withdrawal syndrome. Risk of cleft palate in first trimester.
Excreted in breast milk. Infant sedation and feeding problems reported.
Anxiety, irritability, and panic-like symptoms are very common during perimenopause due to estrogen and progesterone fluctuations. These are frequently treated with benzodiazepines when the underlying cause is hormonal. Benzodiazepines carry significant dependence and cognitive risks, especially for women over 40. Ask your doctor about evaluating hormones before starting an anti-anxiety medication during the menopause transition.
No approved pediatric dosing. Off-label use in adolescents is discouraged; dependence risk is higher in developing brains.
Beers Criteria: high-risk medication in elderly. 3–4× increased hip fracture risk, cognitive impairment, falls.
Dose reduce in severe renal impairment; monitor for excessive sedation.
Hepatic impairment significantly raises alprazolam levels. Start at 25–50% of normal dose.
FDA Adverse Event Reports
Patient-filed reports from the FDA FAERS database · refreshed daily
Community Reports
User-reported experiences - anonymous & anecdotal
Join the Conversation
Premium subscribers can share their experience and confirm others' reports.
Cancel anytime.
Stopping This Medication Safely
Abrupt alprazolam discontinuation can cause life-threatening seizures. Benzodiazepine withdrawal is one of the two withdrawal syndromes (with alcohol) that can be directly fatal. Tapering must be slow and medically supervised.
What Published Research Shows About Stopping This Medication
This summarizes what published research documents, it is not personal medical advice. Any changes to your medication require discussion with your prescribing physician.
- ·Published protocols describe switching to an equivalent dose of a longer-acting benzodiazepine (diazepam) as a first step, this smooths the stopping process significantly
- ·Research supports reducing by no more than 5–10% of total dose every 1–2 weeks, published evidence consistently shows slower reductions are safer
- ·For high-dose or long-term users, published tapering literature documents processes taking 6–24 months
- ·Research supports reducing by no more than 10% of the CURRENT dose (not original dose) per step
- ·The Ashton Manual protocol is widely cited in clinical literature as the reference approach for benzodiazepine stopping
- ·Clinical guidelines recommend monitoring for withdrawal symptoms and pausing dose reductions if symptoms become severe
Warning Symptoms, Contact Your Doctor If You Experience:
- Seizures, call 911 immediately
- Tremors or uncontrollable shaking
- Extreme anxiety or panic disproportionate to your normal level
- Hallucinations or psychosis
- Rapid heartbeat with sweating
- Insomnia that is severe and worsening
Never change or stop a medication without consulting your prescribing physician.
Questions for Your Doctor
$2.99, printable guide for your next appointment
Questions to Ask
- 1.Can we start with therapy or a non-addictive medication instead?
- 2.What is the plan for stopping this medication, and what is the maximum duration you recommend?
- 3.Am I at risk of dependence given my history?
- 4.Are SSRIs or buspirone appropriate for my situation instead?
- 5.What happens to my body if I miss a dose or stop suddenly?
Lab Tests to Request
- Liver function (before long-term use)
- Anxiety scale (GAD-7) to track response
- Depression screen (benzodiazepines can unmask depression)
- Fall risk assessment (elderly)
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Common Questions About Xanax®
Get notified when we update Xanax®
We'll email you when new evidence, safety updates, or alternatives are added.
No spam. Unsubscribe anytime.
Found this useful?
Help keep EvidentMeds editorially independent and community supported. Every dollar funds transparent medication data.